Medline, a leading medical supply manufacturer headquartered in Northfield, Illinois, is embarking on a monumental initial public offering (IPO) with the aim of achieving a staggering $55 billion valuation. This IPO, if successful, would rank as one of the largest listings backed by private equity in history and is indicative of the growing prominence of private equity investments within the healthcare sector.
The company, which is backed by investment giants Blackstone, Carlyle, and Hellman & Friedman, plans to sell 179 million shares at a price range of $26 to $30 each. This offering could potentially raise up to $5.37 billion, providing a significant liquidity event for its private equity owners while also enabling Medline to secure capital for future growth.
Medline's strategic move towards an IPO comes after its acquisition in 2021 by the aforementioned private equity firms for $34 billion, a deal that highlighted the increasing role of private equity in the healthcare industry. The IPO is seen as a crucial indicator of investor appetite for private equity-backed growth companies, particularly as the market heads into 2026.
Founded in 1966 by James and Jon Mills, Medline has transformed into a global supplier of essential medical products, including surgical kits, gloves, and protective apparel for hospitals and nursing homes. For the nine months ending September 27, the company reported impressive financial results, with net sales of $20.6 billion and net income of $977 million, reflecting growth from $18.7 billion in sales and $911 million in income during the same period the previous year.
Notably, several cornerstone investors, including Baillie Gifford, Capital Research, Morgan Stanley’s Counterpoint Global, Durable Capital, Janus Henderson, GIC, and Viking Global, have committed to purchasing up to $2.35 billion in shares. Additionally, the Mills family and their affiliates are set to acquire up to $250 million, demonstrating confidence in the company’s future prospects.
The underwriting team for this IPO is led by Goldman Sachs, Morgan Stanley, BofA Securities, and JP Morgan, which brings a seasoned level of expertise to the offering. Medline plans to list its shares on the Nasdaq under the ticker symbol 'MDLN.'
As the IPO progresses, it will not only serve as a financial milestone for Medline but also potentially reshape the landscape for private equity-backed companies in the healthcare sector. The company’s leadership anticipates that this move will provide necessary capital to fund ongoing growth initiatives, while shareholders and employees alike will closely monitor its market performance and implications.
In terms of regulatory considerations, while the filing does not specify the exact antitrust or regulatory approvals required, it is customary for such significant offerings to undergo scrutiny to ensure compliance with SEC regulations.
In summary, Medline’s IPO is a notable development in the healthcare industry, reflecting both investor confidence and the evolving role of private equity in shaping the future of medical supply businesses.